Detection, verification, and quantification of adverse drug reactions
- PMID: 15231627
- PMCID: PMC443457
- DOI: 10.1136/bmj.329.7456.44
Detection, verification, and quantification of adverse drug reactions
Abstract
The current system of verifying and quantifying adverse reactions to new drugs is too disparate. Epidemiological studies for testing a hypothesis have a part to play in protecting the public from the harmful effects of new drugs
Comment in
-
Making decisions about benefits and harms of medicines.BMJ. 2004 Jul 3;329(7456):47-50. doi: 10.1136/bmj.329.7456.47. BMJ. 2004. PMID: 15231628 Free PMC article. Review.
-
Balancing benefits and harms in health care: technology to collect and share information about harms already exists.BMJ. 2004 Aug 21;329(7463):457; discussion 458-9. doi: 10.1136/bmj.329.7463.457. BMJ. 2004. PMID: 15321908 Free PMC article. No abstract available.
References
-
- Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. Lancet 2002;360: 1590-5. - PubMed
-
- Gale EAM. Lessons from the glitazones: a story of drug development. Lancet 2001;357: 1870-5. - PubMed
-
- Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med 2001;134: 330-4. - PubMed
-
- Maio G. Zur Geschichte der Contergan-Katastrophe im Lichte der Arzneimittelgesetzgebung. Dtsch Med Wochenschr 2001;126: 1183-6. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical